Efficacy/Safety of Pseudoephedrine Plus Levocetirizine Versus Placebo in Patients With Vasomotor Rhinitis
Efficacy and Safety of Cossac L Tablet in Vasomotor Rhinitis Patients : A Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Seoul
-
Dongjak, Seoul, Korea, Republic of, 156-707
- ear, nose and throat, Boramae Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of vasomotor rhinitis
Exclusion Criteria:
- Significant concomitant medical condition
- Use corticosteroids or other allergy medications during the study
- Considered by investigator as not appropriate to participate in the clinical study with othe reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
placebo
|
tablet, BID everyday
Other Names:
|
|
Experimental: Cossac L
Pseudoephedrine 120mg + Levocetirizine 2.5mg
|
tablet, BID everyday
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
TVRSS(Total Vasomotor Rhinitis Symptom Score)
Time Frame: 2week
|
the change from baseline in TVRSS
|
2week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
TVRSS, VRSS
Time Frame: 1week or 2 week
|
|
1week or 2 week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Kyungmi Park, Ph.D., Hanmi Pharmaceutical Company Limited
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Otorhinolaryngologic Diseases
- Nose Diseases
- Rhinitis
- Rhinitis, Vasomotor
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Central Nervous System Stimulants
- Sympathomimetics
- Histamine H1 Antagonists, Non-Sedating
- Vasoconstrictor Agents
- Nasal Decongestants
- Ephedrine
- Pseudoephedrine
- Levocetirizine
Other Study ID Numbers
Other Study ID Numbers
- HM-LCT-301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.